FUSION ANTIBODIES PLC Logo

FUSION ANTIBODIES PLC

FAB | IL

Overview

Corporate Details

ISIN(s):
GB00BDQZGK16
LEI:
213800KBAYRC9VOQ9V39
Country:
United Kingdom
Address:
1 SPRINGBANK ROAD, BT17 0QL BELFAST
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive range of antibody engineering services for therapeutic and diagnostic development. Established in 2001, the company functions as an end-to-end R&D partner, guiding projects from initial antigen design through discovery, engineering, and supply, to pre-clinical cell line development. Its core services include antibody generation, production, characterization, and optimization. Fusion Antibodies emphasizes a collaborative approach, working as an extension of its clients' teams to deliver biologics optimized for long-term manufacturability and commercialization.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for FUSION ANTIBODIES PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-24 11:56
Legal Proceedings Report
Issue Notification: US Patent Update
English 14.4 KB
2025-07-11 08:00
Director's Dealing
Director/PDMR Shareholding
English 24.7 KB
2025-06-02 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 14.0 KB
2025-05-06 11:53
Director's Dealing
Director/PDMR Shareholding
English 24.0 KB
2025-03-24 17:38
Major Shareholding Notification
Holding(s) in Company
English 24.0 KB
2025-03-18 08:00
Share Issue/Capital Change
Placing to raise approximately £1.17 million
English 45.8 KB
2025-02-27 08:00
Regulatory News Service
Contract win
English 16.1 KB
2025-01-31 08:00
M&A Activity
OptiMAL R&D Update
English 15.3 KB
2024-12-04 12:31
Earnings Release
Approval of Grant Funding Application
English 20.4 KB
2024-11-19 08:00
Interim Report
Half-year Report
English 223.0 KB
2024-10-16 14:23
Director's Dealing
Director/PDMR Shareholding
English 24.4 KB
2024-10-16 08:00
Remuneration Information
Issue of shares to non-executive directors
English 34.6 KB
2024-10-08 13:32
Post-Annual General Meeting Information
Result of AGM
English 15.1 KB
2024-10-08 08:00
Pre-Annual General Meeting Information
AGM statement and trading update
English 16.3 KB
2024-10-02 08:00
Delisting Announcement
Block admission six monthly return
English 20.0 KB

Automate Your Workflow. Get a real-time feed of all FUSION ANTIBODIES PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for FUSION ANTIBODIES PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN